“Through this investment, we are reinforcing the unique collaboration that brings together BiomEdit’s state-of-the-art microbiome discovery platform and Nutreco’s customer access and distribution capabilities,” said Fulco van Lede, CEO Nutreco. “We’re excited about its potential to help us super-charge our supply of proprietary ultra-specialty ingredients, speed up progress on our purpose of Feeding the Future and create a more sustainable future for our industry.”
“Nutreco's investment in BiomEdit underscores our strategic partnership and a shared mission to create novel animal health solutions through the untapped potential of the microbiome,” said Aaron Schacht, CEO of BiomEdit. “We are pleased that Nutreco, a global leader in animal nutrition and aquafeed, is joining our roster of world-class Series A investors to help fuel innovation in feed additive products."
Nutreco took the minority stake in BiomEdit through the company’s recent Series A financing round, initially raised in April 2022 in its carve-out from Elanco Animal Health (NYSE: ELAN) including contributions of assets and technology from Ginkgo Bioworks (NYSE: DNA) and Elanco. Anterra Capital, Viking Global Investors and Ferment are also investors in BiomEdit.
